… The benefits of optimal blood pressure (BP) control are well known. For instance, every
10-mm Hg reduction in systolic BP leads to a 13% reduction in all-cause mortality, while …

… –based drugs have proven to be effective in managing high blood pressure in several
clinical trials. As befits a rapidly burgeoning field, there is significant interest in other classes of …

… In this article, we summarize examples of microRNAs and long noncoding RNAs, which …
RNAs and discuss the challenges for translation. Strategies for improving RNA therapeutics and …

… with decreases in systolic blood pressure (>10 mm Hg) and diastolic blood pressure (>5 mm
… Results from Parts B and E were consistent with attenuation of the effect on blood pressure …

… Small interfering RNAs also inhibit translation of target … the RNA-induced silencing complex
to cleave the target mRNA to prevent protein synthesis. A detailed analysis of different RNA …

… of hypertensive patients exhibit uncontrolled blood pressure (BP), … been achieved using
novel RNA therapeutics, including the … RNA therapeutics exploit the fact that virtually all human …

… aPatients previously taking medication for hypertension must be without
antihypertensives for ≥2 weeks prior to screening ABPM, ambulatory blood pressure …

… or decrease of blood pressure. Zilebesiran is a small interfering RNA covalently linked to an
N-… Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J …

… (eg RNA conjugates, polymers, and lipoplexes) that enhance cellular uptake of RNA therapeutics
… A number of small non-coding RNA therapies for cardiovascular indications are now …

… Indeed, rodents exhibit several fundamental differences in certain cardiovascular physiology
elements, such as heart weight, heart rate, blood pressure, and the coronary artery system, …